Hydantoin based inhibitors of MMP13--discovery of AZD6605.
De Savi, C., Waterson, D., Pape, A., Lamont, S., Hadley, E., Mills, M., Page, K.M., Bowyer, J., Maciewicz, R.A.(2013) Bioorg Med Chem Lett 23: 4705-4712
- PubMed: 23810497 
- DOI: https://doi.org/10.1016/j.bmcl.2013.05.089
- Primary Citation of Related Structures:  
4JP4, 4JPA - PubMed Abstract: 
Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chemistry campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimising MMP13 potency, solubility and DMPK properties whilst maintaining good selectivity over MMP14. A number of high quality candidates were progressed and following rat and dog safety evaluation, AZD6605 (3m) was identified as a candidate drug.
Organizational Affiliation: 
Oncology Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. chris.desavi2@astrazeneca.com